Cargando…

Intravitreal Dexamethasone Implant in the Treatment of Non-infectious Uveitis

OBJECTIVES: To evaluate the long-term results of intravitreal dexamethasone implant (DEX) for noninfectious uveitis. MATERIALS AND METHODS: The study included 62 eyes of 44 patients treated with DEX implant due to noninfectious uveitis and followed up for at least a year. Best-corrected visual acuit...

Descripción completa

Detalles Bibliográficos
Autores principales: Hasanreisoğlu, Murat, Özdemir, Hüseyin Baran, Özkan, Kaan, Yüksel, Murat, Aktaş, Zeynep, Atalay, Hatice Tuba, Özdek, Şengül, Gürelik, Gökhan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823586/
https://www.ncbi.nlm.nih.gov/pubmed/31650791
http://dx.doi.org/10.4274/tjo.galenos.2019.81594
_version_ 1783464564384333824
author Hasanreisoğlu, Murat
Özdemir, Hüseyin Baran
Özkan, Kaan
Yüksel, Murat
Aktaş, Zeynep
Atalay, Hatice Tuba
Özdek, Şengül
Gürelik, Gökhan
author_facet Hasanreisoğlu, Murat
Özdemir, Hüseyin Baran
Özkan, Kaan
Yüksel, Murat
Aktaş, Zeynep
Atalay, Hatice Tuba
Özdek, Şengül
Gürelik, Gökhan
author_sort Hasanreisoğlu, Murat
collection PubMed
description OBJECTIVES: To evaluate the long-term results of intravitreal dexamethasone implant (DEX) for noninfectious uveitis. MATERIALS AND METHODS: The study included 62 eyes of 44 patients treated with DEX implant due to noninfectious uveitis and followed up for at least a year. Best-corrected visual acuity (BCVA), central foveal thickness, intraocular pressure (IOP), vitreous haze score, indications, immunomodulatory therapy and steroid usage before/after injection, number of injections, and adverse events were analyzed retrospectively. RESULTS: Average follow-up was 20 months (range 12-64 months). The female/male ratio was 29/15. Mean age was 50 years (range 22-75 years). The most frequent uveitis etiologies were idiopathic (25 patients, 40.3%) and Behçet’s uveitis. (17 patients, 27.4%) The signedmost common indication for DEX injection was cystoid macular edema together with resistant vitreous haze (26 eyes, 41.9%). Twenty-two eyes (30%) received more than one DEX injection. Mean BCVA was improved from 0.55 logMAR at baseline to 0.38, 0.32, and 0.35 after 1, 3, and 6 months, respectively (p<0.001 for each). Mean CFT was decreased from 386 μm at baseline to 288, 311, and 302 μm after 1, 3, and 6 months, respectively (p<0.001 for each). Mean IOP did not change significantly during follow-up. Five eyes (8%) received topical anti-glaucoma medication (IOP ≥25 mmHg). Eighteen (46%) of 39 phakic eyes underwent cataract surgery during follow-up. Similar efficacy of the DEX implant was observed in eyes that received multiple injections. Systemic immunomodulatory therapy did not change significantly during follow-up. CONCLUSION: Intravitreal DEX injection does not alter systemic immunomodulatory therapy, but may facilitate the management of noninfectious uveitis by suppressing local intraocular inflammation. Multiple injections yielded comparable visual and anatomical outcomes to single injections. Follow-up for ocular hypertension and cataract formation are important, especially in eyes receiving multiple injections.
format Online
Article
Text
id pubmed-6823586
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Galenos Publishing
record_format MEDLINE/PubMed
spelling pubmed-68235862019-11-07 Intravitreal Dexamethasone Implant in the Treatment of Non-infectious Uveitis Hasanreisoğlu, Murat Özdemir, Hüseyin Baran Özkan, Kaan Yüksel, Murat Aktaş, Zeynep Atalay, Hatice Tuba Özdek, Şengül Gürelik, Gökhan Turk J Ophthalmol Original Article OBJECTIVES: To evaluate the long-term results of intravitreal dexamethasone implant (DEX) for noninfectious uveitis. MATERIALS AND METHODS: The study included 62 eyes of 44 patients treated with DEX implant due to noninfectious uveitis and followed up for at least a year. Best-corrected visual acuity (BCVA), central foveal thickness, intraocular pressure (IOP), vitreous haze score, indications, immunomodulatory therapy and steroid usage before/after injection, number of injections, and adverse events were analyzed retrospectively. RESULTS: Average follow-up was 20 months (range 12-64 months). The female/male ratio was 29/15. Mean age was 50 years (range 22-75 years). The most frequent uveitis etiologies were idiopathic (25 patients, 40.3%) and Behçet’s uveitis. (17 patients, 27.4%) The signedmost common indication for DEX injection was cystoid macular edema together with resistant vitreous haze (26 eyes, 41.9%). Twenty-two eyes (30%) received more than one DEX injection. Mean BCVA was improved from 0.55 logMAR at baseline to 0.38, 0.32, and 0.35 after 1, 3, and 6 months, respectively (p<0.001 for each). Mean CFT was decreased from 386 μm at baseline to 288, 311, and 302 μm after 1, 3, and 6 months, respectively (p<0.001 for each). Mean IOP did not change significantly during follow-up. Five eyes (8%) received topical anti-glaucoma medication (IOP ≥25 mmHg). Eighteen (46%) of 39 phakic eyes underwent cataract surgery during follow-up. Similar efficacy of the DEX implant was observed in eyes that received multiple injections. Systemic immunomodulatory therapy did not change significantly during follow-up. CONCLUSION: Intravitreal DEX injection does not alter systemic immunomodulatory therapy, but may facilitate the management of noninfectious uveitis by suppressing local intraocular inflammation. Multiple injections yielded comparable visual and anatomical outcomes to single injections. Follow-up for ocular hypertension and cataract formation are important, especially in eyes receiving multiple injections. Galenos Publishing 2019-10 2019-10-24 /pmc/articles/PMC6823586/ /pubmed/31650791 http://dx.doi.org/10.4274/tjo.galenos.2019.81594 Text en © Copyright 2019 by Turkish Ophthalmological Association | Turkish Journal of Ophthalmology, published by Galenos Publishing House. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Hasanreisoğlu, Murat
Özdemir, Hüseyin Baran
Özkan, Kaan
Yüksel, Murat
Aktaş, Zeynep
Atalay, Hatice Tuba
Özdek, Şengül
Gürelik, Gökhan
Intravitreal Dexamethasone Implant in the Treatment of Non-infectious Uveitis
title Intravitreal Dexamethasone Implant in the Treatment of Non-infectious Uveitis
title_full Intravitreal Dexamethasone Implant in the Treatment of Non-infectious Uveitis
title_fullStr Intravitreal Dexamethasone Implant in the Treatment of Non-infectious Uveitis
title_full_unstemmed Intravitreal Dexamethasone Implant in the Treatment of Non-infectious Uveitis
title_short Intravitreal Dexamethasone Implant in the Treatment of Non-infectious Uveitis
title_sort intravitreal dexamethasone implant in the treatment of non-infectious uveitis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823586/
https://www.ncbi.nlm.nih.gov/pubmed/31650791
http://dx.doi.org/10.4274/tjo.galenos.2019.81594
work_keys_str_mv AT hasanreisoglumurat intravitrealdexamethasoneimplantinthetreatmentofnoninfectiousuveitis
AT ozdemirhuseyinbaran intravitrealdexamethasoneimplantinthetreatmentofnoninfectiousuveitis
AT ozkankaan intravitrealdexamethasoneimplantinthetreatmentofnoninfectiousuveitis
AT yukselmurat intravitrealdexamethasoneimplantinthetreatmentofnoninfectiousuveitis
AT aktaszeynep intravitrealdexamethasoneimplantinthetreatmentofnoninfectiousuveitis
AT atalayhaticetuba intravitrealdexamethasoneimplantinthetreatmentofnoninfectiousuveitis
AT ozdeksengul intravitrealdexamethasoneimplantinthetreatmentofnoninfectiousuveitis
AT gurelikgokhan intravitrealdexamethasoneimplantinthetreatmentofnoninfectiousuveitis